Wada makes appeal decision on Iga Swiatek drugs ban
Share:
The five-time grand slam champion accepted a one month suspension after testing positive for a banned substance in August. The World Anti-Doping Agency (Wada) has said that it will not lodge an appeal to the Court of Arbitration for Sport (Cas) in the case of Iga Swiatek after the former World No 1 tested positive for prohibited substance trimetazidine (TMZ).
The five-time grand slam champion had accepted a one-month suspension in November after testing positive for TMZ in an out-of-competition sample in August which was caused by contamination of her medication melatonin. Swiatek had said she had been taking it for jet lag and sleep issues and did not receive a lengthy ban after the International Tennis Integrity Agency (ITIA) ruled there was no significant fault or negligence on her part.
"Wada has conducted a full review of the case file related to the ITIA decision, which it received on 29 November," Wada said in a statement. "Wada’s scientific experts have confirmed that the specific contaminated melatonin scenario, as presented by the athlete and accepted by the ITIA, is plausible and that there would be no scientific grounds to challenge it at Cas.".
